- Home
- FLNC vs ORIC Comparison
FLNC vs ORIC Comparison
Compare FLNC & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLNC | ORIC |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.7M | 783.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FLNC | ORIC |
|---|---|---|
| Price | $22.97 | $8.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 12 |
| Target Price | $14.05 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 5.0M | 1.4M |
| Earning Date | 02-09-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,262,830,000.00 | N/A |
| Revenue This Year | $50.83 | N/A |
| Revenue Next Year | $20.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.46 | $3.90 |
| 52 Week High | $25.85 | $14.93 |
Technical Indicators
Market Signals| Indicator | FLNC | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 60.41 | 28.24 |
| Support Level | $19.49 | $7.96 |
| Resistance Level | $20.95 | $8.44 |
| Average True Range (ATR) | 1.85 | 0.42 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 61.23 | 10.92 |
Price Performance
Historical ComparisonAbout FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.